Lipid accumulation in the vascular wall and in the myocardium causes serious cardiovascular alterations in pathologies such as: atherosclerosis, ischemic cardiomyopathy and diabetic cardiomyopathy; all of them, diseases with high prevalence in the current society. Ischemic cardiomyopathy is the first death cause in occidental countries and myocardia heart attack is the leading cause of 50% of the deaths in this group. In 2030 the cardiovascular disease will be the first cause of death (40%) in elderly population (>65 years-old).
Given the clinical impact of the cardiovascular system lipid accumulation, urgent specific treatments for its reduction are needed. The experimental findings of the Lipid and Cardiovascular pathology group from CSIC and IIBB, and led by Dra. Vicenta C. Llorente have demonstrated the existence of a new key pathway in vascular and myocardia lipid accumulation.
Iproteos has designed a battery of peptidomimetics in order to disrupt a PPI involved in the pathway of lipid accumulation.